middle.news
Telix Surges with $204M Q2 Revenue, Launches Gozellix Amid SEC Inquiry
6:03pm on Tuesday 22nd of July, 2025 AEST
•
Healthcare
Read Story
Telix Surges with $204M Q2 Revenue, Launches Gozellix Amid SEC Inquiry
6:03pm on Tuesday 22nd of July, 2025 AEST
Key Points
Q2 2025 revenue up 63% to $204 million
U.S. launch of Gozellix with HCPCS reimbursement code secured
ProstACT Global Phase 3 trial reaches key patient recruitment milestone
New manufacturing facilities operational in Japan and Belgium
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE